228 related articles for article (PubMed ID: 28688221)
1. Minimal factor XIII activity level to prevent major spontaneous bleeds.
Menegatti M; Palla R; Boscarino M; Bucciarelli P; Muszbek L; Katona E; Makris M; Peyvandi F;
J Thromb Haemost; 2017 Sep; 15(9):1728-1736. PubMed ID: 28688221
[TBL] [Abstract][Full Text] [Related]
2. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.
Peyvandi F; Palla R; Menegatti M; Siboni SM; Halimeh S; Faeser B; Pergantou H; Platokouki H; Giangrande P; Peerlinck K; Celkan T; Ozdemir N; Bidlingmaier C; Ingerslev J; Giansily-Blaizot M; Schved JF; Gilmore R; Gadisseur A; Benedik-Dolničar M; Kitanovski L; Mikovic D; Musallam KM; Rosendaal FR;
J Thromb Haemost; 2012 Apr; 10(4):615-21. PubMed ID: 22321862
[TBL] [Abstract][Full Text] [Related]
3. Clinical Use of Factor XIII Concentrates.
Lassila R
Semin Thromb Hemost; 2016 Jun; 42(4):440-4. PubMed ID: 27071044
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Ashley C; Chang E; Davis J; Mangione A; Frame V; Nugent DJ
Haemophilia; 2015 Jan; 21(1):102-8. PubMed ID: 25377187
[TBL] [Abstract][Full Text] [Related]
5. Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.
Kerlin BA; Inbal A; Will A; Williams M; Garly ML; Jacobsen L; Kearney SL
J Thromb Haemost; 2017 Aug; 15(8):1601-1606. PubMed ID: 28581691
[TBL] [Abstract][Full Text] [Related]
6. Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories.
Jennings I; Kitchen S; Menegatti M; Palla R; Walker I; Makris M; Peyvandi F
Int J Lab Hematol; 2017 Aug; 39(4):350-358. PubMed ID: 28406553
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients.
Williams M; Will A; Stenmo C; Rosholm A; Tehranchi R
Haemophilia; 2014 Jan; 20(1):99-105. PubMed ID: 23834599
[TBL] [Abstract][Full Text] [Related]
8. [Factor XIII deficiency - not only a congenital bleeding disorder].
Schött U; Astermark J; Zdanowski A; Strandberg K
Lakartidningen; 2023 Apr; 120():. PubMed ID: 37099358
[TBL] [Abstract][Full Text] [Related]
9. Factor XIII deficiency.
Hsieh L; Nugent D
Haemophilia; 2008 Nov; 14(6):1190-200. PubMed ID: 19141159
[TBL] [Abstract][Full Text] [Related]
10. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency.
Naderi M; Dorgalaleh A; Alizadeh S; Tabibian S; Hosseini S; Shamsizadeh M; Bamedi T
Int J Hematol; 2014 Nov; 100(5):443-9. PubMed ID: 25230816
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Nugent DJ; Ashley C; García-Talavera J; Lo LC; Mehdi AS; Mangione A
Haemophilia; 2015 Jan; 21(1):95-101. PubMed ID: 25458735
[TBL] [Abstract][Full Text] [Related]
12. Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency.
Wada H; Souri M; Matsumoto R; Sugihara T; Ichinose A
Thromb Haemost; 2013 Apr; 109(4):661-8. PubMed ID: 23407795
[TBL] [Abstract][Full Text] [Related]
13. Blood coagulation factor XIII and factor XIII deficiency.
Dorgalaleh A; Rashidpanah J
Blood Rev; 2016 Nov; 30(6):461-475. PubMed ID: 27344554
[TBL] [Abstract][Full Text] [Related]
14. Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
Pitkänen HH; Jouppila A; Lemponen M; Ilmakunnas M; Ahonen J; Lassila R
Thromb Res; 2017 Jan; 149():56-61. PubMed ID: 27902939
[TBL] [Abstract][Full Text] [Related]
15. Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity.
Leitner M; Büchold C; Pasternack R; Binder NB; Moore GW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498248
[TBL] [Abstract][Full Text] [Related]
16. Long-term prophylaxis in patients with severe congenital factor XIII deficiency is not complicated by inhibitor formation.
Naderi M; Ahmadinejad M; Hosseini MS; Moradi E; Dorgalaleh A; Shamsizadeh M
Blood Coagul Fibrinolysis; 2017 Jun; 28(4):276-278. PubMed ID: 27306330
[TBL] [Abstract][Full Text] [Related]
17. Factor XIII deficiency: complete phenotypic characterization of two cases with novel causative mutations.
Katona É; Muszbek L; Devreese K; Kovács KB; Bereczky Z; Jonkers M; Shemirani AH; Mondelaers V; Ermens AA
Haemophilia; 2014 Jan; 20(1):114-20. PubMed ID: 24118344
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.
Kerlin B; Brand B; Inbal A; Halimeh S; Nugent D; Lundblad M; Tehranchi R
J Thromb Haemost; 2014 Dec; 12(12):2038-43. PubMed ID: 25263390
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
Lovejoy AE; Reynolds TC; Visich JE; Butine MD; Young G; Belvedere MA; Blain RC; Pederson SM; Ishak LM; Nugent DJ
Blood; 2006 Jul; 108(1):57-62. PubMed ID: 16556896
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Factor XIII.
Muszbek L; Katona É; Kerényi A
Methods Mol Biol; 2017; 1646():277-293. PubMed ID: 28804836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
